At Hudson Therapeutics, Inc., we are on a mission to enhance and restore patients' lives by advancing novel compounds into innovative drugs through an extensive global clinical development process. Our commitment to innovation, strategic partnerships, and patient-centricity drives every aspect of our work.
Hudson Therapeutics, Inc. is a subsidiary of Shaperon, Inc., which is the listed on Kosdaq in South Korea. With a team of experienced experts and a relentless commitment to excellence, we have taken the legacy of Shaperon, Inc. to new heights.
Business Development (BD) experts at Hudson Therapeutics, Inc. play a crucial role in our success. They work to license out assets from Shaperon, Inc. to global pharmaceutical leaders. Our partners trust us to deliver innovation that transforms lives.
Our clinical experts at Hudson Theapeutics, Inc. manage global clinical trials for these assets after obtaining Investigational New Drug (IND) approvals. We're committed to ensuring that these potential breakthroughs reach patients around the world.
© 2023 Hudson Therapeutics, Inc.
The information presented on this website is derived from the official website of our parent company, Shaperon, Inc. This site is designed exclusively to showcase Hudson Therapeutics, Inc. to potential investors and partners. Please note that we are not responsible for any misuse of the content outside its intended purpose.